- Home
- NERV vs ERNA Comparison
NERV vs ERNA Comparison
Compare NERV & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- ERNA
- Stock Information
- Founded
- NERV 2007
- ERNA 2018
- Country
- NERV United States
- ERNA United States
- Employees
- NERV N/A
- ERNA N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- ERNA Biotechnology: Pharmaceutical Preparations
- Sector
- NERV Health Care
- ERNA Health Care
- Exchange
- NERV Nasdaq
- ERNA Nasdaq
- Market Cap
- NERV 12.0M
- ERNA 13.5M
- IPO Year
- NERV 2014
- ERNA N/A
- Fundamental
- Price
- NERV $2.00
- ERNA $2.21
- Analyst Decision
- NERV Hold
- ERNA
- Analyst Count
- NERV 1
- ERNA 0
- Target Price
- NERV $5.00
- ERNA N/A
- AVG Volume (30 Days)
- NERV 17.0K
- ERNA 49.8K
- Earning Date
- NERV 08-05-2025
- ERNA 08-12-2025
- Dividend Yield
- NERV N/A
- ERNA N/A
- EPS Growth
- NERV N/A
- ERNA N/A
- EPS
- NERV 0.83
- ERNA N/A
- Revenue
- NERV N/A
- ERNA $535,000.00
- Revenue This Year
- NERV N/A
- ERNA N/A
- Revenue Next Year
- NERV N/A
- ERNA N/A
- P/E Ratio
- NERV $2.40
- ERNA N/A
- Revenue Growth
- NERV N/A
- ERNA 365.22
- 52 Week Low
- NERV $1.15
- ERNA $1.75
- 52 Week High
- NERV $3.35
- ERNA $33.00
- Technical
- Relative Strength Index (RSI)
- NERV 62.19
- ERNA 52.83
- Support Level
- NERV $1.94
- ERNA $1.91
- Resistance Level
- NERV $2.32
- ERNA $2.12
- Average True Range (ATR)
- NERV 0.14
- ERNA 0.12
- MACD
- NERV 0.03
- ERNA 0.06
- Stochastic Oscillator
- NERV 56.55
- ERNA 95.35
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.